Introduction Executive Summary Axial spondyloarthritis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Axial spondyloarthritis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Axial spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Axial spondyloarthritis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Bimekizumab: UCB Biopharma • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Namilumab: Izana Bioscience • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis KIN-1901: Kinevant Sciences • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Axial spondyloarthritis Key Companies Axial spondyloarthritis Key Products Axial spondyloarthritis- Unmet Needs Axial spondyloarthritis- Market Drivers and Barriers Axial spondyloarthritis- Future Perspectives and Conclusion Axial spondyloarthritis Analyst Views Axial spondyloarthritis Key Companies Appendix

Table 1 Total Products for Axial spondyloarthritis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Pfizer • Mycenax Biotech • Clover Biopharmaceuticals • Celltrion • UCB • Gilead Sciences • Amgen • Genrix (Shanghai) Biopharmaceuticals • Sun Pharma Global • Boehringer Ingelheim • Jiangsu HengRui Medicine • Izana Bioscience • 3SBio • Tasly Pharmaceuticals Inc. • Suzhou Zelgen Biopharmaceuticals • Affibody • Kinevant Sciences • Qyuns Therapeutics • Akeso Biopharma • Jiangsu HengRui Medicine Co., Ltd • FunPep Co Ltd. • Luye Pharma Group • siRNAgen Therapeutics • Aclaris Therapeutics • Dice molecules